Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

autogene cevumeran (RG6180)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BioNTech, Roche

Drug class:

Immunostimulant

Related drugs:

‹

astuprotimut-R (0)

tirvalimogene teraplasmid (2)

Histone H3.3-K27M Neoantigen Vaccine Therapy (1)

sipuleucel-T (1)

Versamune HPV (1)

aDC1 vaccine (0)

Ad-CCL21-DC (0)

AdHER2/neu DC Vaccine (0)

allogeneic K562-GM tumor cell vaccine (0)

allogeneic Myeloma GM-CSF Vaccine (0)

bioengineered allogeneic immune cells (0)

velimogene aliplasmid (0)

alpha-lactalbumin vaccine (0)

APVAC1 vaccine (0)

autologous Tcm cellular immunotherapy (0)

BCG vaccine (0)

interferon alpha 2b (0)

dasiprotimut-T (0)

BN-Brachyury (0)

CD25hi Treg depleted DLI (0)

Escherichia coli (0)

recombinant human papillomavirus bivalent vaccine (0)

dendritic cell vaccine (0)

cancer vaccine MUC-1 (0)

DC-AdGMCAIX (0)

autologous dendritic cell vaccine leaded with autologous tumor cell lysate (0)

Dendritic cell renal cell carcinoma fusion vaccine (0)

DNAJB1-PRKACA peptide vaccine (0)

EP-101 STEMVAC (0)

FR Alpha Peptide Vaccine (0)

Fusion-VAC-XS15 (0)

human papillomavirus 9-valent vaccine, recombinant (0)

types 6, 11, 16, 18 (0)

gp96-Ig vaccine (0)

GSK2130579A (0)

GSK2302032A (0)

GVAX leukemia vaccine (0)

GVAX lung cancer vaccine (0)

H1299 cell lysate with iscomatrix adjuvant vaccine (0)

H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant (0)

HER2- and HER3-primed dendritic cells (0)

HER-2 pulsed DC1 (0)

HRXG-K-1939 (0)

IDH1R132H peptide vaccine (0)

autologous γδ T lymphocytes (0)

iNeo-Vac-P01 (0)

iNeo-Vac-R01 (0)

KRAS peptide vaccine (0)

axalimogene filolisbac (0)

mammaglobin-A DNA vaccine (0)

autologous dendritic cell vaccine (0)

multi-epitope melanoma peptide (0)

MVA-BN-Brachyury IV vaccine (0)

neoantigen DNA vaccine (0)

neoantigen peptide vaccine (0)

NEO_PLIN2101 (0)

nonavalent HPV vaccine (0)

NUMARZU-001 (0)

NY-ESO-1 combined with MPLA vaccine (0)

NY-ESO-1 Iscomatrix (0)

ruxotemitide (0)

oral therapeutic vaccine V3-X (0)

p.DOM-WT1-126 DNA vaccine (0)

PEG IFN-a 2b (0)

PF-06753512 (0)

PF-07263689 (0)

pING-hHER3FL (0)

PNV21 vaccine (0)

Poly-ICLC matured DC adjuvanted NY-ESO-1/Melan-A-MART-1 peptide vaccine (0)

PolyPEPI 1018 (0)

polyvalent vaccine-KLH conjugate (0)

rilimogene galvacirepvec (0)

HSP Gp96 vaccine (0)

RNA-NP vaccine (0)

self-amplifying RNA cancer vaccine (0)

BCG vaccine (0)

SQZ-PBMC-HPV (0)

EGFREDVmiR-16 (0)

TG01 vaccine (0)

live attenuated bacillus Calmette-Guerin (0)

CMV-MVA vaccine (0)

TVI-Brain-1 (0)

Undisclosed ovarian cancer vaccine (0)

Undisclosed VLP vaccine (0)

alpha-tocopheroloxyacetic acid (0)

VV-GMCSF-Lact (0)

astuprotimut-R (0)

›

PD-L1 underexpression	Triple Negative Breast Cancer	PD-L1 underexpression	Triple Negative Breast Cancer	atezolizumab + RG6180 Sensitive: C3 – Early Trials atezolizumab + RG6180 Sensitive : C3	atezolizumab + RG6180 Sensitive: C3 – Early Trials atezolizumab + RG6180 Sensitive : C3
PD-L1 underexpression	Colorectal Cancer	PD-L1 underexpression	Colorectal Cancer	atezolizumab + RG6180 Sensitive: C3 – Early Trials atezolizumab + RG6180 Sensitive : C3	atezolizumab + RG6180 Sensitive: C3 – Early Trials atezolizumab + RG6180 Sensitive : C3
PD-L1 underexpression	Melanoma	PD-L1 underexpression	Melanoma	atezolizumab + RG6180 Sensitive: C3 – Early Trials atezolizumab + RG6180 Sensitive : C3	atezolizumab + RG6180 Sensitive: C3 – Early Trials atezolizumab + RG6180 Sensitive : C3
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	atezolizumab + RG6180 Sensitive: C3 – Early Trials atezolizumab + RG6180 Sensitive : C3	atezolizumab + RG6180 Sensitive: C3 – Early Trials atezolizumab + RG6180 Sensitive : C3